The rating particularly states that Andrey is “well versed in all aspects of intellectual property and can hammer out favourable outcomes in difficult disputes in the life sciences, fast-moving consumer goods and high-technology spheres” and Boris is “a trusted adviser to numerous pharmaceutical companies on both the patent and trademark sides, and has further know-how in advertising and data protection.

On January 10, changes to transactions with cash or other assets subject to mandatory control came into force.

New amendments are introduced to the Order of the Russian Government dated 16.03.2020 No. 635-r “On temporary restriction of entry into the Russian Federation of foreign citizens and stateless persons and temporary suspension of registration and issuance of visas and invitations” (the “Order”).

To prevent the direct implementation of provisions of the Joint Stock Companies (hereinafter-JSC) legislation in the Charters, draft laws that soften the requirements for Charters were introduced to the State Duma of the Russian Federation.

Lidings’ dispute resolution practice partner Stepan Guzey will take part in the online discussion Leading Arbitration Cases 2020: Different Perspectives.

The Supreme court has amended the regulation of pledges, established by the Supreme Arbitration Court of the Russian Federation earlier. The Decree of the Plenum of the Supreme Court No. 45 "On some issues of dispute resolution connected to pledge" dated 24.12.2020 (hereinafter – DPSC No. 45) derogates the Decree of the Plenum dated 12.07.2012 No. 42 (hereinafter – DPSAC No. 42) and resolves main problems raised in connection with the reform of this institute in 2015.

Lidings’ managing partner Andrey Zelenin heading the firm’s Pharmaceuticals and Healthcare industry practice and partner Boris Malakhov, Head of the Intellectual Property practice of the firm, run a special webinar on the key market developments in the healthcare and life sciences sector in Russia.

Starting from the beginning of 2021, new rules for the retail sale of goods (the “Rules”) entered into force. The Rules will be valid until January 1, 2027. The Rules are developed within the framework of the regulatory guillotine and replace a few previously existing documents (rules for retail trade, rules for distance selling of goods, rules for commission trading).

On January 5, 2021 the Decree of the Government of the Russian Federation No. 3718-r dated December 31, 2020 (the Decree) was published. In accordance with the Decree, Pharmasintez JSC, a Russian generic company, has been granted a 1-year compulsory license to use the inventions of the US companies Gilead Sciences Inc. and Gilead Pharmasset LLC protecting Remdesivir subject to a “fair compensation”¹.